CORRESP Filing
Akari Therapeutics Plc
Date: July 30, 2025 · CIK: 0001541157 · Accession: 0001641172-25-021570
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289056
Letter
Akari Therapeutics, PLC
Boston Wharf Road Fl. 7
Boston, MA 02210
July 30, 2025
Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Re: Akari Therapeutics PLC
Registration Statement on Form S-3 File No. 333-289056
VIA EDGAR
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics PLC (the " Registrant ") hereby respectfully requests that the effectiveness of the Registration Statement on Form S-3 (File No. 333-289056) of the Registrant (the " Registration Statement ") be accelerated so that the Company's Registration Statement will be declared effective at 5:00 p.m., Eastern Time, on July 31, 2025 or as soon thereafter as may be practicable.
The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Greenberg Traurig, LLP, by calling Win Rutherfurd at (305) 579 0769. The Company hereby authorizes Mr. Rutherfurd to orally modify or withdraw this request for acceleration.
Very truly yours,
AKARI THERAPEUTICS PLC
Show Raw Text
CORRESP 1 filename1.htm Akari Therapeutics, PLC 22 Boston Wharf Road Fl. 7 Boston, MA 02210 July 30, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Akari Therapeutics PLC Registration Statement on Form S-3 File No. 333-289056 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics PLC (the " Registrant ") hereby respectfully requests that the effectiveness of the Registration Statement on Form S-3 (File No. 333-289056) of the Registrant (the " Registration Statement ") be accelerated so that the Company's Registration Statement will be declared effective at 5:00 p.m., Eastern Time, on July 31, 2025 or as soon thereafter as may be practicable. The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Greenberg Traurig, LLP, by calling Win Rutherfurd at (305) 579 0769. The Company hereby authorizes Mr. Rutherfurd to orally modify or withdraw this request for acceleration. Very truly yours, AKARI THERAPEUTICS PLC By: /s/ Torsten Hombeck Name: Torsten Hombeck Title: Chief Financial Officer cc: Win Rutherfurd (Greenberg Traurig, LLP)